Privia Health Group (NASDAQ:PRVA) Posts Earnings Results, Beats Estimates By $0.12 EPS

Key Points

• Privia reported quarterly EPS of $0.21, beating the $0.09 consensus, while revenue of $656.96 million exceeded estimates and rose 13.2% year over year. EPS was down from $0.29 a year earlier.
• The company raised its 2026 outlook above the high end of its initial guidance; at midpoint, it expects adjusted EBITDA growth of 23.9%, practice collections growth of 13.1%, and care margin growth of 16.3%.
• Privia agreed to acquire American Choice Healthcare’s MSSP ACO for about $36 million, adding more than 36,000 attributed lives expected to contribute to growth beginning in 2027.

Privia Health Group (NASDAQ:PRVA - Get Free Report) released its quarterly earnings results on Thursday. The company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.12, FiscalAI reports. Privia Health Group had a net margin of 1.19% and a return on equity of 3.52%. The business had revenue of $656.96 million for the quarter, compared to analysts' expectations of $610.72 million. During the same period in the previous year, the company earned $0.29 earnings per share. The firm's revenue for the quarter was up 13.2% compared to the same quarter last year.

Here are the key takeaways from Privia Health Group's conference call:

• Privia raised its 2026 outlook above the high end of initial guidance across key financial metrics. At the guidance midpoints, adjusted EBITDA is expected to grow 23.9%, practice collections 13.1%, and care margin 16.3% year over year.
• Strong execution drove 12.2% growth in implemented providers and 19.2% growth in attributed lives year over year through the first nine months; adjusted EBITDA rose 21.9% to $114.7 million. Management cited operating leverage, with EBITDA reaching 28.8% of care margin.
• Privia agreed to acquire American Choice Healthcare’s MSSP ACO for about $36 million in cash. The ACO is expected to bring more than 36,000 attributed lives across 10 existing and three new states beginning in 2027, with minimal impact on 2026 results and a positive contribution to 2027 lives and adjusted EBITDA.
• The company expects free-cash-flow conversion of roughly 70%–75% of adjusted EBITDA, citing taxes and the timing of MSSP-related payments; it had previously guided to 70%–80%. Privia ended Q3 with $446.3 million in cash and no debt, and expects at least $520 million at year-end.

Privia Health Group Stock Performance

Privia Health Group stock traded up $0.48 during mid-day trading on Friday, reaching $24.42. The company's stock had a trading volume of 2,807,727 shares, compared to its average volume of 1,143,537. The company has a market capitalization of $3.12 billion, a P/E ratio of 93.93 and a beta of 0.76. Privia Health Group has a 12-month low of $18.92 and a 12-month high of $28.82. The firm's fifty day moving average price is $21.04 and its two-hundred day moving average price is $22.64.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Privia Health Group in a research report on Tuesday, September 29th. Zacks Research upgraded Privia Health Group from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 5th. Citigroup reaffirmed a "buy" rating on shares of Privia Health Group in a research report on Thursday, July 23rd. Piper Sandler boosted their price target on shares of Privia Health Group from $36.00 to $38.00 and gave the stock an "overweight" rating in a report on Friday. Finally, Canaccord Genuity Group boosted their price target on shares of Privia Health Group from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Friday. Eleven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.23.

Privia Health Group News Roundup

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Privia reported Q3 earnings of $0.21 per share, above the $0.09 consensus estimate, and revenue of $656.96 million versus expectations of $610.72 million. Revenue rose 13.2% year over year. Privia Health Q3 results
• Positive Sentiment: The company raised full-year 2026 guidance across all key financial metrics. Year-to-date adjusted EBITDA was $114.7 million, up 21.9% from the same period in 2025, supporting the improved outlook. Privia Health Q3 results
• Positive Sentiment: Canaccord Genuity raised its price target from $32 to $33 and maintained a Buy rating. Piper Sandler raised its target from $36 to $38 and kept an Overweight rating, signaling increased analyst confidence. Canaccord Genuity price-target update Piper Sandler ratings
• Positive Sentiment: A valuation analysis argued that PRVA could be undervalued following its earnings beat, adding to the positive post-results narrative. Privia Health valuation analysis
• Negative Sentiment: Despite beating estimates, reported quarterly EPS of $0.21 was below the $0.29 reported a year earlier, a potential caveat for investors weighing the strong revenue growth and raised guidance.

About Privia Health Group

Privia Health Group, Inc is a physician-enablement company that partners with independent medical practices to support the delivery of coordinated, value-based care. The company provides an integrated platform designed to help physicians manage clinical, administrative and financial functions while maintaining ownership and control of their practices.

Its services include practice management, electronic health record and technology support, revenue-cycle management, payer contracting, population-health analytics, care-management programs and administrative assistance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.